Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Non-Current Liabilities (2021 - 2025)

ARS Pharmaceuticals' Other Non-Current Liabilities history spans 2 years, with the latest figure at $4.6 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $4.6 million; the TTM value through Dec 2025 reached $4.6 million, changed N/A, while the annual FY2025 figure was $4.6 million, N/A changed from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $4.6 million at ARS Pharmaceuticals, up from $3.8 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $4.6 million in Q4 2025 and bottomed at $83000.0 in Q4 2021.